Neurocrine Biosciences, Inc. · Health Care
Neurocrine Biosciences focuses on discovery and commercialization of targeted therapeutics for neurological, neuroendocrine, and neuropsychiatric disorders. The stock is primarily driven by solid volume expansion for INGREZZA alongside the ongoing commercial execution and label expansion for newly launched crinecerfont.
The AlphaInsight Score is a proprietary 0–100 composite of momentum, valuation, growth and safety factors. Research snapshot updated 2026-09-05.
NBIX scores 82 out of 100 on the AlphaInsight composite— higher than roughly 88% of the 656 stocks in our research universe, and #5 among the 73 Health Care names we cover. The composite blends momentum, valuation, growth and safety factors.NBIX's strongest pillar right now is growth (85/100), while valuation (68/100) is where the score gives ground.
On the fundamentals: a market capitalization of roughly $16 billion, a P/E ratio of 24.3, trailing EPS growth of 35.7%, year-over-year revenue growth of 19.4%. It pays no meaningful dividend, so returns come from price appreciation rather than income.
From a risk and timing standpoint, shares have historically moved less than the broad market (beta 0.5); the 14-day RSI sits at 56, a neutral zone between oversold and overbought; the current technical setup reads: Consolidating above the 50-day moving average after an earnings breakout.
NBIX operates in the Biotechnology industry within the Health Care sector. The bull and bear cases below summarize where our research sees the balance of opportunity and risk in the stock right now.
Sustained revenue growth from INGREZZA across tardive dyskinesia and chorea associated with Huntington's disease generates substantial free cash flow. The launch of crinecerfont in congenital adrenal hyperplasia adds a second multi-hundred-million-dollar franchise, diversifying revenue away from a single asset. Robust early-to-mid stage pipelines in psychiatry and focal onset seizures provide long-term optionality.
Heavy concentration on INGREZZA leaves the business vulnerable to Medicare Part D renegotiations or competitive pressure from Teva's AUSTEDO. Pipeline clinical trial setbacks in neuropsychiatry could dampen future growth multiples. Increasing SG&A and clinical R&D costs may temporarily compress operating margins.
Neurocrine Biosciences, Inc. scores 82/100 on the AlphaInsight Score — ranked #64 of 656 stocks in our research universe. It blends momentum (78/100), valuation (68/100), growth (85/100) and safety (84/100).
NBIX currently carries an AlphaInsight Score of 82/100 in our research system. Subscribers receive daily entry, target and stop-loss levels whenever it appears in a slate.
Heavy concentration on INGREZZA leaves the business vulnerable to Medicare Part D renegotiations or competitive pressure from Teva's AUSTEDO. Pipeline clinical trial setbacks in neuropsychiatry could dampen future growth multiples. Increasing SG&A and clinical R&D costs may temporarily compress operating margins.
Compare NBIX head-to-head with BIIB, INCY, UTHR on AlphaInsight Scores, valuation, growth and safety factors.
Subscribers get the complete thesis, risk factors and technical breakdown for NBIXand 10 researched ideas every trading day.
Cancel anytime · Secure checkout
Ready-to-paste citation snippets for forums, Reddit, X or your own site.
[NBIX stock research — AlphaInsight Score & technical signals](https://alphainsightai.net/stocks/NBIX)<a href="https://alphainsightai.net/stocks/NBIX">NBIX stock research — AlphaInsight Score & technical signals</a>